Leading the way
Sanford Burnham Prebys Medical Discovery Institute has deep expertise in fundamental biologyand one of the most comprehensive drug discovery centers in the nonprofit world that accelerates the translation of our discoveries toward patient benefit.
Who we are
Sanford Burnham Prebys discoveries begin with our people – scientists, postdoctoral candidates, graduate students and support staff – who work collaboratively toward understanding the cause of disease and identifying new therapeutic approaches to improve human health.
As an independent, nonprofit institution, we focus on conducting biomedical research in cancer, neuroscience, immunolgy and rare children’s diseases.
The Institute is home to one of the most comprehensive drug discovery centers in the nonprofit world.
Our innovative approach to research underpins our strategic partnerships with the biotech and pharmaceutical industry.
We cultivate the next generation of biomedical scientists through our graduate and postdoctoral training programs.
Sanford Burnham Prebys employs more than 700 scientists and staff in San Diego (La Jolla), CA. We are widely recognized for our NCI-designated Cancer Center, the Conrad Prebys Center for Chemical Genomics and the Sanford Children’s Health Research Center.
Our approach to improving human health is built on three principles
Our track record of pioneering research spans more than 40 years, and has produced breakthrough discoveries in cancer, neuroscience, immunology and rare children's diseases.Learn More
We operate one of the most advanced drug discovery centers in the world that leverages biomedical discoveries to develop prototype drugs.Learn More
Education and training
We are committed to education and training the next generation of scientific leaders to ensure our legacy continues.Learn More
Years of pioneering research
Patents issued to date
Clinical trials underway
FDA-approved treatments and tests
Suzuki H, Kumar SA, Shuai S, Diaz-Navarro A, Gutierrez-Fernandez A, De Antonellis P, Cavalli FMG, Juraschka K, Farooq H, Shibahara I, Vladoiu MC, Zhang J, Abeysundara N, Przelicki D, Skowron P, Gauer N, Luu B, Daniels C, Wu X, Forget A, Momin A, Wang J, Dong W, Kim SK, Grajkowska WA, Jouvet A, Fèvre-Montange M, Garrè ML, Rao AAN, Giannini C, Kros JM, French PJ, Jabado N, Ng HK, Poon WS, Eberhart CG, Pollack IF, Olson JM, Weiss WA, Kumabe T, López-Aguilar E, Lach B, Massimino M, Van Meir EG, Rubin JB, Vibhakar R, Chambless LB, Kijima N, Klekner A, Bognár L, Chan JA, Faria CC, Ragoussis J, Pfister SM, Goldenberg A, Wechsler-Reya RJ, Bailey SD, Garzia L, Morrissy AS, Marra MA, Huang X, Malkin D, Ayrault O, Ramaswamy V, Puente XS, Calarco JA, Stein L, Taylor MD
Nature 2019 Oct 9 ;
Loss of the FOXP1 Transcription Factor Leads to Deregulation of B Lymphocyte Development and Function at Multiple Stages.
Dekker JD, Baracho GV, Zhu Z, Ippolito GC, Schmitz RJ, Rickert RC, Tucker HO
Immunohorizons 2019 Oct 7 ;3(10):447-462
Time course of blood and brain cytokine/chemokine levels following adolescent alcohol exposure and withdrawal in rats.
Sanchez-Alavez M, Nguyen W, Mori S, Wills DN, Otero D, Aguirre CA, Singh M, Ehlers CL, Conti B
Alcohol Clin Exp Res 2019 Oct 7 ;
Endurance training remodels skeletal muscle phospholipid composition and increases intrinsic mitochondrial respiration in men with type 2 diabetes.
Pino MF, Stephens NA, Eroshkin AM, Yi F, Hodges A, Cornnell HH, Pratley RE, Smith SR, Wang M, Han X, Coen PM, Goodpaster BH, Sparks LM
Physiol Genomics 2019 Oct 7 ;
Absence of HIF1A leads to glycogen accumulation and an inflammatory response that enables pancreatic tumor growth.
Maruggi M, Layng FIAL, Lemos R, Garcia G, James BP, Sevilla M, Soldevila F, Baaten BJG, de Jong PR, Koh MY, Powis G
Cancer Res 2019 Oct 4 ;
Wolf AR, Wesener DA, Cheng J, Houston-Ludlam AN, Beller ZW, Hibberd MC, Giannone RJ, Peters SL, Hettich RL, Leyn SA, Rodionov DA, Osterman AL, Gordon JI
Cell Host Microbe 2019 Sep 24 ;